JPMorgan lowered the firm’s price target on Evolent Health (EVH) to $12 from $13 and keeps an Overweight rating on the shares. Evolent Health has acquired three businesses since 2020 that have significantly increased its runway for growth, with much remaining as healthcare transitions to a new payment mode, the analyst tells investors in a research note. The firm believes P&L accountability of the execution of the strategy will be demonstrated in the forward results.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health price target raised to $13 from $12 at Citizens JMP
- Evolent Health’s AI Strategy: Navigating Risks and Challenges Amidst Technological Advancements
- Evolent Health Inc. Reports Mixed Earnings Results
- Evolent Health: Strong Long-Term Outlook with Projected 20%+ Annual EBITDA Growth and Improved Visibility
- Evolent Health price target lowered to $16 from $17 at Piper Sandler
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue